News

Two Additional Amino Acids in Toxic Protein Sequence Form Resilient Alzheimer’s Plaques, Study Shows

Researchers at Virginia Commonwealth University (VCU) have found that the presence of two additional amino acids in the amyloid beta (Aβ) protein sequence forms the basis of amyloid plaque formation and Alzheimer’s disease development. Their study, “Few Ramachandran Angle Changes Provide Interaction Strength Increase in Aβ42 versus Aβ40 Amyloid Fibrils,” appeared…

Alzheimer’s Breakthrough Team to Compete for XPrize Launch of Effort for Early Detection

More 100 neurologists, other scientists and disease advocates are supporting the Alzheimer’s Breakthrough team in its goal of getting “launched” at next month’s XPRIZE summit. Their effort centers on crowdsourcing, attracting a worldwide spectrum of experts and innovators to develop new technologies focused on brain health. These technologies encompass artificial intelligence, biotechnology, precision pharmaceuticals, physics…

First Phase 1 Trial Participant Receives HTL0016878, Heptares’ Therapy for Cognitive Impairment in Alzheimer’s

The first participant in a Phase 1 clinical trial of HTL0016878 as a treatment for cognitive impairment in Alzheimer’s disease is receiving the therapy, according to its developer, Heptares Therapeutics. Heptares, a subsidiary of Japan’s Sosei Group Corporation, and Ireland-based Allergan are partnering in the trial under a treatment development and…